Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

B van Veggel; J F Vilacha Madeira R Santos; S M S Hashemi; M S Paats; K Monkhorst; D A M Heideman; M Groves; T Radonic; E F Smit; E Schuuring; A J van der Wekken; A J de Langen

doi:10.1016/j.lungcan.2019.12.013

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

B van Veggel
, J F Vilacha Madeira R Santos
, S M S Hashemi
, M S Paats
, K Monkhorst
, D A M Heideman
, M Groves
, T Radonic
, E F Smit
, E Schuuring
, A J van der Wekken
, A J de Langen

Antoni van Leeuwenhoek Hospital
University of Groningen, Faculty of Science and Engineering, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Dept of Pulmonary Diseases, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands.
Dept of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, The Netherlands.
Dep of Pathology and Medical Biology, University of Groningen and University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Dept of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

OBJECTIVES: Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4-10 % of EGFR mutations in non-small cell lung cancer (NSCLC) and are associated with primary resistance to first and second generation EGFR tyrosine kinase inhibitors (TKIs). In vitro and preclinical animal studies have shown that osimertinib exerts antitumor activity against EGFR exon 20 mutation positive NSCLC. We report on a cohort of advanced stage NSCLC patients who harbor an EGFR exon 20 mutation and received osimertinib treatment.

MATERIAL AND METHODS: Twenty-one patients were treated with osimertinib 80 or 160 mg once daily from April 2016 to June 2018, in four institutions in the Netherlands. Data were obtained retrospectively. Progression free survival (PFS), disease control rate (DCR), overall survival (OS) and objective response rate (ORR) were assessed using RECIST v1.1.

RESULTS: Thirteen patients received prior platinum-based chemotherapy, and three patients a first - or second generation EGFR TKI. We observed 1 partial response, 17 patients with stable disease and 3 with progressive disease as best response to osimertinib (ORR 5 %). Median PFS was 3.6 (95 % CI, 2.6-4.5) months. PFS did not differ for patients with co-occurring TP53 mutations (p = 0.937). The DCR at three months was 71 %. Median OS was 8.7 (95 % CI, 1.1-16.4) months.

CONCLUSION: Osimertinib has limited antitumor activity in patients with EGFR exon 20 mutated NSCLC, with an ORR of 5 %.

Original language	English
Pages (from-to)	9-13
Number of pages	5
Journal	Lung Cancer
Volume	141
Early online date	20 Dec 2019
DOIs	https://doi.org/10.1016/j.lungcan.2019.12.013
Publication status	Published - 1 Mar 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

EGFR exon 20 mutation
Non-small cell lung cancer
Osimertinib

Access to Document

10.1016/j.lungcan.2019.12.013

Cite this

van Veggel, B., Madeira R Santos, J. F. V., Hashemi, S. M. S., Paats, M. S., Monkhorst, K., Heideman, D. A. M., Groves, M., Radonic, T., Smit, E. F., Schuuring, E., van der Wekken, A. J., & de Langen, A. J. (2020). Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer, 141, 9-13. https://doi.org/10.1016/j.lungcan.2019.12.013

@article{bc94b790f0c14dd3be798e57ee5aecf6,

title = "Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer",

abstract = "OBJECTIVES: Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4-10 \% of EGFR mutations in non-small cell lung cancer (NSCLC) and are associated with primary resistance to first and second generation EGFR tyrosine kinase inhibitors (TKIs). In vitro and preclinical animal studies have shown that osimertinib exerts antitumor activity against EGFR exon 20 mutation positive NSCLC. We report on a cohort of advanced stage NSCLC patients who harbor an EGFR exon 20 mutation and received osimertinib treatment.MATERIAL AND METHODS: Twenty-one patients were treated with osimertinib 80 or 160 mg once daily from April 2016 to June 2018, in four institutions in the Netherlands. Data were obtained retrospectively. Progression free survival (PFS), disease control rate (DCR), overall survival (OS) and objective response rate (ORR) were assessed using RECIST v1.1.RESULTS: Thirteen patients received prior platinum-based chemotherapy, and three patients a first - or second generation EGFR TKI. We observed 1 partial response, 17 patients with stable disease and 3 with progressive disease as best response to osimertinib (ORR 5 \%). Median PFS was 3.6 (95 \% CI, 2.6-4.5) months. PFS did not differ for patients with co-occurring TP53 mutations (p = 0.937). The DCR at three months was 71 \%. Median OS was 8.7 (95 \% CI, 1.1-16.4) months.CONCLUSION: Osimertinib has limited antitumor activity in patients with EGFR exon 20 mutated NSCLC, with an ORR of 5 \%.",

keywords = "EGFR exon 20 mutation, Non-small cell lung cancer, Osimertinib",

author = "\{van Veggel\}, B and \{Madeira R Santos\}, \{J F Vilacha\} and Hashemi, \{S M S\} and Paats, \{M S\} and K Monkhorst and Heideman, \{D A M\} and M Groves and T Radonic and Smit, \{E F\} and E Schuuring and \{van der Wekken\}, \{A J\} and \{de Langen\}, \{A J\}",

year = "2020",

month = mar,

day = "1",

doi = "10.1016/j.lungcan.2019.12.013",

language = "English",

volume = "141",

pages = "9--13",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

AU - van Veggel, B

AU - Madeira R Santos, J F Vilacha

AU - Hashemi, S M S

AU - Paats, M S

AU - Monkhorst, K

AU - Heideman, D A M

AU - Groves, M

AU - Radonic, T

AU - Smit, E F

AU - Schuuring, E

AU - van der Wekken, A J

AU - de Langen, A J

PY - 2020/3/1

Y1 - 2020/3/1

N2 - OBJECTIVES: Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4-10 % of EGFR mutations in non-small cell lung cancer (NSCLC) and are associated with primary resistance to first and second generation EGFR tyrosine kinase inhibitors (TKIs). In vitro and preclinical animal studies have shown that osimertinib exerts antitumor activity against EGFR exon 20 mutation positive NSCLC. We report on a cohort of advanced stage NSCLC patients who harbor an EGFR exon 20 mutation and received osimertinib treatment.MATERIAL AND METHODS: Twenty-one patients were treated with osimertinib 80 or 160 mg once daily from April 2016 to June 2018, in four institutions in the Netherlands. Data were obtained retrospectively. Progression free survival (PFS), disease control rate (DCR), overall survival (OS) and objective response rate (ORR) were assessed using RECIST v1.1.RESULTS: Thirteen patients received prior platinum-based chemotherapy, and three patients a first - or second generation EGFR TKI. We observed 1 partial response, 17 patients with stable disease and 3 with progressive disease as best response to osimertinib (ORR 5 %). Median PFS was 3.6 (95 % CI, 2.6-4.5) months. PFS did not differ for patients with co-occurring TP53 mutations (p = 0.937). The DCR at three months was 71 %. Median OS was 8.7 (95 % CI, 1.1-16.4) months.CONCLUSION: Osimertinib has limited antitumor activity in patients with EGFR exon 20 mutated NSCLC, with an ORR of 5 %.

AB - OBJECTIVES: Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4-10 % of EGFR mutations in non-small cell lung cancer (NSCLC) and are associated with primary resistance to first and second generation EGFR tyrosine kinase inhibitors (TKIs). In vitro and preclinical animal studies have shown that osimertinib exerts antitumor activity against EGFR exon 20 mutation positive NSCLC. We report on a cohort of advanced stage NSCLC patients who harbor an EGFR exon 20 mutation and received osimertinib treatment.MATERIAL AND METHODS: Twenty-one patients were treated with osimertinib 80 or 160 mg once daily from April 2016 to June 2018, in four institutions in the Netherlands. Data were obtained retrospectively. Progression free survival (PFS), disease control rate (DCR), overall survival (OS) and objective response rate (ORR) were assessed using RECIST v1.1.RESULTS: Thirteen patients received prior platinum-based chemotherapy, and three patients a first - or second generation EGFR TKI. We observed 1 partial response, 17 patients with stable disease and 3 with progressive disease as best response to osimertinib (ORR 5 %). Median PFS was 3.6 (95 % CI, 2.6-4.5) months. PFS did not differ for patients with co-occurring TP53 mutations (p = 0.937). The DCR at three months was 71 %. Median OS was 8.7 (95 % CI, 1.1-16.4) months.CONCLUSION: Osimertinib has limited antitumor activity in patients with EGFR exon 20 mutated NSCLC, with an ORR of 5 %.

KW - EGFR exon 20 mutation

KW - Non-small cell lung cancer

KW - Osimertinib

UR - https://www.scopus.com/pages/publications/85077438149

U2 - 10.1016/j.lungcan.2019.12.013

DO - 10.1016/j.lungcan.2019.12.013

M3 - Article

SN - 0169-5002

VL - 141

SP - 9

EP - 13

JO - Lung Cancer

JF - Lung Cancer

ER -

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this